A 90-day repeated-dose oral toxicological evaluation was conducted according to GLP and OECD guidelines on lyophilized spores of the novel genetically modified strain ZB183. Lyophilized spores at doses of 10, 10, and 10 CFU/kg body weight/day were administered by oral gavage to Wistar rats for a period of 90 consecutive days. ZB183 had no effects on clinical signs, mortality, ophthalmological examinations, functional observational battery, body weights, body weight gains and food consumption in both sexes. There were no test item-related changes observed in haematology, coagulation, urinalysis, thyroid hormonal analysis, terminal fasting body weights, organ weights, gross pathology and histopathology. A minimal increase in the plasma albumin level was observed at 10 and 10 CFU/kg/day doses without an increase in total protein in males or females and was considered a nonadverse effect. The "No Observed Adverse Effect Level (NOAEL)" is defined at the highest dose of 10 CFU/kg body weight/day for lyophilized ZB183 Spores under the test conditions employed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875028 | PMC |
http://dx.doi.org/10.1155/2019/3042108 | DOI Listing |
J Toxicol
November 2019
ZBiotics Company, 181 2nd St., San Francisco, CA 94105, USA.
A 90-day repeated-dose oral toxicological evaluation was conducted according to GLP and OECD guidelines on lyophilized spores of the novel genetically modified strain ZB183. Lyophilized spores at doses of 10, 10, and 10 CFU/kg body weight/day were administered by oral gavage to Wistar rats for a period of 90 consecutive days. ZB183 had no effects on clinical signs, mortality, ophthalmological examinations, functional observational battery, body weights, body weight gains and food consumption in both sexes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!